Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H24N2O8 |
Molecular Weight | 444.4346 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C[C@@]3([H])C(C(=O)C4=C(O)C=CC=C4[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C
InChI
InChIKey=OFVLGDICTFRJMM-WESIUVDSSA-N
InChI=1S/C22H24N2O8/c1-21(31)8-5-4-6-11(25)12(8)16(26)13-9(21)7-10-15(24(2)3)17(27)14(20(23)30)19(29)22(10,32)18(13)28/h4-6,9-10,15,25,27-28,31-32H,7H2,1-3H3,(H2,23,30)/t9-,10-,15-,21+,22-/m0/s1
Molecular Formula | C22H24N2O8 |
Molecular Weight | 444.4346 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Discovered as natural products from actinomycetes soil bacteria, the tetracyclines were first reported in the scientific literature in 1948. They were noted for their broad spectrum antibacterial activity and were commercialized with clinical success beginning in the late 1940s to the early 1950s. By catalytic hydrogenation of Aureomycin, using palladium metal and hydrogen, the C7 deschloro derivative was synthesized, producing a compound of higher potency, a better solubility profile, and favorable pharmacological activity; it was subsequently named tetracycline. Tetracyclines are primarily bacteriostatic and exert their antimicrobial effect by the inhibition of protein synthesis by binding to the 30S ribosomal subunit. Tetracycline is active against a broad range of gram-negative and gram-positive organisms. Tetracycline is indicated in the treatment of infections caused by susceptible strains. To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline
hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or
prevent infections that are proven or strongly suspected to be caused by bacteria.
Originator
Sources: http://pubs.acs.org/doi/abs/10.1021/ja01114a057 | http://pubs.acs.org/doi/abs/10.1021/ja01114a537
Curator's Comment: References retrieved from https://www.ncbi.nlm.nih.gov/pubmed/13117662 # Pfizer and Lederle Laboratories
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2363135 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | TETRACYCLINE HYDROCHLORIDE Approved UseTetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below:
• Upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae and Hemophilus influenzae. Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible.
• Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae,
Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.)
• Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus.
(Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.)
• Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections,
Q fever, rickettsialpox.
• Psittacosis caused by Chlamydophila psittaci.
• Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal
infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum.
• Granuloma inquinale caused by Klebsiella granulomatis.
• Relapsing fever caused by Borrelia sp.
• Bartonellosis caused by Bartonella bacilliformis.
• Chancroid caused by Hemophilus ducreyi.
• Tularemia caused by Francisella tularensis.
• Plaque caused by Yersinia pestis.
• Cholera caused by Vibrio cholerae.
• Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside).
• Infections due to Campylobacter fetus.
• As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica.
• Urinary tract infections caused by susceptible strains of Escherichia coli, Klebsiella, etc.
• Other infections caused by susceptible gram-negative organisms such as E. coli, Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp.
• In severe acne, adjunctive therapy with tetracycline may be useful.
When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections:
• Syphilis and yaws caused by Treponema pallidum and pertenue, respectively,
• Vincent’s infection caused by Fusobacterium fusiforme,
• Infections caused by Neisseria gonorrhoeae,
• Anthrax caused by Bacillus anthracis,
• Infections due to Listeria monocytogenes,
• Actinomycosis caused by Actinomyces species,
• Infections due to Clostridium species. Launch Date-5.05007997E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/856000/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
2.6 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/856000/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
2.7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/856000/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT |
|
4.5 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/856000/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
4.5 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/856000/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
4.1 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/856000/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2.5 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6487493/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
27.27 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6487493/ |
300 mg 2 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TETRACYCLINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
25.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/856000/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
27 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/856000/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
31.7 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/856000/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT |
|
55.7 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/856000/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
56.6 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/856000/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
74.7 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/856000/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
26.91 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6487493/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/856000/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
5.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/856000/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
6.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/856000/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT |
|
6.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/856000/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
6.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/856000/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
8.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/856000/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
7.85 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6487493/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
1000 mg 1 times / day multiple, oral Recommended Dose: 1000 mg, 1 times / day Route: oral Route: multiple Dose: 1000 mg, 1 times / day Sources: |
unhealthy, 14 - 35 years n = 31 Health Status: unhealthy Condition: acne Age Group: 14 - 35 years Sex: M+F Population Size: 31 Sources: |
|
2.2 |500 mg/mL|mg 2 times / day multiple, topical|oral (complex) Dose: 2.2 |500 mg/mL|mg, 2 times / day Route: topical|oral Route: multiple Dose: 2.2 |500 mg/mL|mg, 2 times / day Sources: |
unhealthy, 14 - 35 years n = 36 Health Status: unhealthy Condition: acne Age Group: 14 - 35 years Sex: M+F Population Size: 36 Sources: |
Other AEs: Discoloration skin... |
250 mg 4 times / day multiple, oral Recommended Dose: 250 mg, 4 times / day Route: oral Route: multiple Dose: 250 mg, 4 times / day Sources: |
unhealthy, 38 years n = 1 Health Status: unhealthy Condition: pharyngitis Age Group: 38 years Sex: M Population Size: 1 Sources: |
Disc. AE: Mucosal ulceration... AEs leading to discontinuation/dose reduction: Mucosal ulceration (1 patient) Sources: |
7 g multiple, intrapleural (total) Overdose Dose: 7 g Route: intrapleural Route: multiple Dose: 7 g Sources: |
unhealthy, 41 years n = 1 Health Status: unhealthy Age Group: 41 years Sex: M Population Size: 1 Sources: |
Disc. AE: Pleural disorder... AEs leading to discontinuation/dose reduction: Pleural disorder Sources: |
2 % 2 times / day multiple, intralesional Dose: 2 %, 2 times / day Route: intralesional Route: multiple Dose: 2 %, 2 times / day Sources: |
unhealthy, 63 years (range: 53–72 years) n = 21 Health Status: unhealthy Condition: lower eyelid festoons Age Group: 63 years (range: 53–72 years) Sex: M+F Population Size: 21 Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Discoloration skin | 2.2 |500 mg/mL|mg 2 times / day multiple, topical|oral (complex) Dose: 2.2 |500 mg/mL|mg, 2 times / day Route: topical|oral Route: multiple Dose: 2.2 |500 mg/mL|mg, 2 times / day Sources: |
unhealthy, 14 - 35 years n = 36 Health Status: unhealthy Condition: acne Age Group: 14 - 35 years Sex: M+F Population Size: 36 Sources: |
|
Mucosal ulceration | 1 patient Disc. AE |
250 mg 4 times / day multiple, oral Recommended Dose: 250 mg, 4 times / day Route: oral Route: multiple Dose: 250 mg, 4 times / day Sources: |
unhealthy, 38 years n = 1 Health Status: unhealthy Condition: pharyngitis Age Group: 38 years Sex: M Population Size: 1 Sources: |
Pleural disorder | Disc. AE | 7 g multiple, intrapleural (total) Overdose Dose: 7 g Route: intrapleural Route: multiple Dose: 7 g Sources: |
unhealthy, 41 years n = 1 Health Status: unhealthy Age Group: 41 years Sex: M Population Size: 1 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
[Acute nephrosis following enterocolitis due to tetracycline]. | 1967 Sep 15 |
|
Iliacus haematoma syndrome as a complication of anticoagulant therapy. | 1968 Oct 12 |
|
Polyuric acute renal failure after methoxyflurane and tetracycline. | 1971 Dec 11 |
|
Protective effect of ascorbic acid, isoascorbic acid and mannitol against tetracycline-induced nephrotoxicity. | 1971 Jul |
|
Benign intracranial hypertension. Sequel to tetracycline therapy in a child. | 1971 May 31 |
|
Benign intracranial hypertension after antibiotic therapy. | 1972 Jul 1 |
|
Disseminated intravascular coagulation associated with tetracycline-induced hepatorenal failure during pregnancy. | 1973 Feb 15 |
|
Megaloblastic anemia associated with long-term tetracycline therapy. Report of a case. | 1973 Jun |
|
Protein synthesis in Mycobacterium tuberculosis H37Rv and the effect of streptomycin in streptomycin-susceptible and -resistant strains. | 1973 Sep |
|
Tetracycline-induced immune hemolytic anemia. | 1974 May-Jun |
|
[Tetracyclin intoxication versus idiopathic pancreatitis: report of a case with multiple organ involvement (author's transl)]. | 1979 |
|
Tetracycline-induced aplastic anemia. | 1979 Mar |
|
Drug-induced myocarditis: a report of two cases. | 1979 May-Jun |
|
Effect of toxic doses of progesterone on hepatotoxic effects of tetracycline. | 1985 Apr |
|
Congenital heart disease in relation to maternal use of Bendectin and other drugs in early pregnancy. | 1985 Aug 8 |
|
Hemolytic anemia after tetracycline therapy. | 1985 Mar 28 |
|
Selective absorption of ultraviolet laser energy by human atherosclerotic plaque treated with tetracycline. | 1985 May 1 |
|
Minor complication of thyroid cyst sclerosis with tetracycline. | 1986 Jan |
|
Pseudotumor cerebri--a complication of tetracycline treatment of acne. | 1986 Mar |
|
An aborted, prospective, randomized trial of sclerotherapy for prolonged drainage after mastectomy. | 1986 May |
|
[Effectiveness of legalon and essentiale in a tetracycline-induced liver lesion]. | 1986 Oct |
|
Continuous thoracic epidural analgesia for the control of pain associated with pleural sclerosis. | 1989 Jan |
|
Susceptibilities of Mycoplasma hominis and Ureaplasma urealyticum to two new quinolones, sparfloxacin and WIN 57273. | 1991 Jul |
|
Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro. | 2000 Jul 28 |
|
Human organic anion transporters mediate the transport of tetracycline. | 2002 Jan |
|
Use of a low-density microarray for studying gene expression patterns induced by hepatotoxicants on primary cultures of rat hepatocytes. | 2003 Oct |
|
The outcome of pseudotumor cerebri induced by tetracycline therapy. | 2004 Dec |
|
A novel action of minocycline: inhibition of human immunodeficiency virus type 1 infection in microglia. | 2004 Oct |
|
Minocycline inhibits apoptosis and inflammation in a rat model of ischemic renal injury. | 2004 Oct |
|
[Intracranial hypertension with severe and irreversible reduced acuity and impaired visual fields after oral tetracycline]. | 2005 Aug 20 |
|
Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis isolates. | 2005 Nov |
|
[Intracranial hypertension with ocular manifestation during the use of tetracycline: case report]. | 2005 Sep-Oct |
|
Investigation of proteomic biomarkers in in vivo hepatotoxicity study of rat liver: toxicity differentiation in hepatotoxicants. | 2006 Feb |
|
Hepatic gene expression profiling and lipid homeostasis in mice exposed to steatogenic drug, tetracycline. | 2006 Nov |
|
Newer tetracycline derivatives: synthesis, anti-HIV, antimycobacterial activities and inhibition of HIV-1 integrase. | 2007 Apr 15 |
|
Doxycycline-induced amnesia: a case report. | 2007 Jan |
|
The effect of azithromycin on reactive oxygen species in rosacea. | 2007 Mar |
|
Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. | 2007 Mar |
|
Synthesis and in vitro evaluation of targeted tetracycline derivatives: effects on inhibition of matrix metalloproteinases. | 2007 Mar 15 |
|
Tetracycline-induced renal failure after dental treatment. | 2009 Jan |
|
Protective effect of bicyclol on tetracycline-induced fatty liver in mice. | 2009 Jul 10 |
|
Epidural abscess caused by community-associated methicillin-resistant Staphylococcus aureus strain USA300 in Japan. | 2010 Oct |
|
Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature. | 2010 Sep |
|
Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen. | 2011 Aug |
|
Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent. | 2012 Jan 26 |
|
Model steatogenic compounds (amiodarone, valproic acid, and tetracycline) alter lipid metabolism by different mechanisms in mouse liver slices. | 2014 |
|
Gene expression markers in the zebrafish embryo reflect a hepatotoxic response in animal models and humans. | 2014 Oct 1 |
|
Multiparametric assay using HepaRG cells for predicting drug-induced liver injury. | 2015 Jul 2 |
|
Increased hepatic Fatty Acid uptake and esterification contribute to tetracycline-induced steatosis in mice. | 2015 Jun |
Patents
Sample Use Guides
TETRACYCLINE HYDROCHLORIDE - tetracycline hydrochloride capsule
Adults: Usual daily dose, 1 gram as 500 mg twice a day or 250 mg four times a day. Higher doses such as 500 mg four times a day may be required for severe infections or for those infections which do not respond to the smaller doses.
For pediatric patients above eight years of age: Usual daily dose, 10 mg/lb to 20 mg/lb (25mg/kg to 50 mg/kg) body weight divided in four equal doses.
TETRACYCLINE VISION 10 mg/g eye ointment
Adults and children: depending on the severity of condition, a strip of the eye ointment with length of 1 – 1.5 cm is inserted into the conjunctival fold of the lower eyelid 3 - 4 times daily and in more severe cases, up to 6 times daily.
Route of Administration:
Other
Standard tetracycline powders should provide the following range of Minimal Inhibitory Concentration values:
Enterococcus faecalis ATCC 29212 8 - 32 mcg/mL
Escherichia coli ATCC 25922 0.5 - 2 mcg/mL
Haemophilus influenzae ATCC 49247 4 - 32 mcg/mL
Mycoplasma pneumoniae ATCC 29342 0.06-0.5 mcg/mL
Staphylococcus aureus ATCC 29213 0.12 - 1 mcg/mL
Streptococcus pneumoniae ATCC 49619 0.06 - 0.5 mcg/mL
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 16:02:24 UTC 2022
by
admin
on
Fri Dec 16 16:02:24 UTC 2022
|
Record UNII |
F8VB5M810T
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LIVERTOX |
NBK547920
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
||
|
CFR |
21 CFR 520.2345B
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
||
|
CFR |
21 CFR 520.2345C
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
||
|
WHO-VATC |
QA02BD02
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
||
|
NDF-RT |
N0000007948
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
||
|
WHO-VATC |
QJ51AA07
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
||
|
WHO-VATC |
QD06AA54
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
||
|
WHO-ATC |
S01AA09
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
||
|
WHO-ATC |
D06AA04
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
||
|
WHO-ATC |
J01AA20
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
||
|
CFR |
21 CFR 556.720
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
21.1
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
||
|
WHO-VATC |
QA01AB13
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
||
|
WHO-ATC |
J01AA07
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
||
|
WHO-VATC |
QG51AA02
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
||
|
WHO-VATC |
QG01AA90
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
||
|
NDF-RT |
N0000007948
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
||
|
WHO-VATC |
QS01AA09
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
||
|
WHO-ATC |
S03AA02
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
||
|
WHO-ATC |
J01RA08
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
||
|
NCI_THESAURUS |
C1595
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
||
|
WHO-ATC |
S02AA08
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
||
|
CFR |
21 CFR 520.2345E
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
||
|
WHO-ATC |
A02BD08
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
||
|
CFR |
21 CFR 520.2345A
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
||
|
WHO-VATC |
QG51AG03
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
||
|
CFR |
21 CFR 520.2345D
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
||
|
WHO-VATC |
QS02AA08
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
||
|
CFR |
21 CFR 520.2345
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
||
|
WHO-VATC |
QD06AA04
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
||
|
WHO-ATC |
A01AB13
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
||
|
NDF-RT |
N0000175505
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
||
|
WHO-VATC |
QS03AA02
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
||
|
WHO-ATC |
A02BD02
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
||
|
WHO-VATC |
QJ01AA07
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
D013752
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
PRIMARY | |||
|
298
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
PRIMARY | |||
|
CHEMBL1440
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
PRIMARY | |||
|
F8VB5M810T
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
PRIMARY | |||
|
SUB10942MIG
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
PRIMARY | |||
|
60-54-8
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
PRIMARY | |||
|
27902
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
PRIMARY | |||
|
200-481-9
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
PRIMARY | |||
|
DB00759
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
PRIMARY | |||
|
2611
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
PRIMARY | |||
|
DTXSID7023645
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
PRIMARY | |||
|
TETRACYCLINE
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
PRIMARY | |||
|
108579
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
PRIMARY | |||
|
F8VB5M810T
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
PRIMARY | |||
|
10395
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
PRIMARY | RxNorm | ||
|
3188
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
PRIMARY | |||
|
77932
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
PRIMARY | |||
|
C865
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
PRIMARY | |||
|
M10611
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
PRIMARY | Merck Index | ||
|
Tetracycline
Created by
admin on Fri Dec 16 16:02:24 UTC 2022 , Edited by admin on Fri Dec 16 16:02:24 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
TRANSPORTER -> SUBSTRATE |
|
||
|
TARGET ORGANISM->INHIBITOR |
18 STRAINS; LESS THE 8 ng/mL for some strains; MIC range listed
MIC90
|
||
|
SOLVATE->ANHYDROUS | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
BINDER->LIGAND |
BINDING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
MIC | BIOLOGICAL |
|
SUSCEPTIBILITY: RESISTANT |
|
||
MIC | BIOLOGICAL |
|
PATHOGEN: S. PNEUMONIAE, BRUCELLA spp., BACILLUS ANTRHACIS |
|
||
MIC | BIOLOGICAL |
|
SUSCEPTIBILITY: SUSCEPTIBLE |
|
||
MIC | BIOLOGICAL |
|
SUSCEPTIBILITY: INTERMEDIATE |
|
||
Tmax | PHARMACOKINETIC |
|
ROUTE OF ADMINISTRATION: ORAL |
|
||
MIC | BIOLOGICAL |
|
PATHOGEN: S. PNEUMONIAE |
|
||
MIC | BIOLOGICAL |
|
PATHOGEN: ACINETOBACTER spp., ENTEROBACTERIACEAE, S. AUREUS, V. CHOLREAE, Y. PESTIS |
|
||
Biological Half-life | PHARMACOKINETIC |
|
|
|||
MIC | BIOLOGICAL |
|
SUSCEPTIBILITY: INTERMEDIATE |
|
||
MIC | BIOLOGICAL |
|
PATHOGEN: H. INFLUENZAE, S. PYOGENES |
|
||